Meeting Abstract

Emicizumab Versus Immunosuppression for Acquired Hemophilia. (AHA)


Authors listHart, Christina; Klamroth, Robert; Sachs, Ulrich J.; Greil, Richard; Knoebl, Paul N.; Oldenburg, Johannes; Miesbach, Wolfgang; Pfrepper, Christian; Trautmann-Grill, Karolin; Pekrul, Isabell; Holstein, Katharina; Eichler, Hermann; Weigt, Carmen; Schipp, Dorothea; Werwitzke, Sonja; Tiede, Andreas

Publication year2023

JournalBlood

Volume number142

ISSN0006-4971

eISSN1528-0020

Open access statusBronze

DOI Linkhttps://doi.org/10.1182/blood-2023-174958

Conference65th Annual Meeting of the American-Society-of-Hematology (ASH)

PublisherAmerican Society of Hematology (ASH Publications)



Citation Styles

Harvard Citation styleHart, C., Klamroth, R., Sachs, U., Greil, R., Knoebl, P., Oldenburg, J., et al. (2023) Emicizumab Versus Immunosuppression for Acquired Hemophilia. (AHA), Blood, 142. https://doi.org/10.1182/blood-2023-174958

APA Citation styleHart, C., Klamroth, R., Sachs, U., Greil, R., Knoebl, P., Oldenburg, J., Miesbach, W., Pfrepper, C., Trautmann-Grill, K., Pekrul, I., Holstein, K., Eichler, H., Weigt, C., Schipp, D., Werwitzke, S., & Tiede, A. (2023). Emicizumab Versus Immunosuppression for Acquired Hemophilia. (AHA). Blood. 142. https://doi.org/10.1182/blood-2023-174958


Last updated on 2025-10-06 at 12:03